Trials / Completed
CompletedNCT03222609
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 191 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Tablet; Oral |
| DRUG | Navitoclax | Film-coated tablet; Oral |
Timeline
- Start date
- 2017-10-31
- Primary completion
- 2022-03-28
- Completion
- 2025-01-29
- First posted
- 2017-07-19
- Last updated
- 2026-01-20
- Results posted
- 2025-03-12
Locations
91 sites across 14 countries: United States, Australia, Canada, Croatia, Greece, Hungary, Israel, Italy, Japan, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03222609. Inclusion in this directory is not an endorsement.